These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39251367)

  • 1. The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney.
    Wang Q; Munteanu B; Marker A; Luo Y; Holz C; Kane JL; Kuntzweiler T; Poulton EJ; Sedic M; Jayyosi Z; Riedel J; Fretland J
    Drug Metab Dispos; 2024 Oct; 52(11):1288-1296. PubMed ID: 39251367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
    Dankers AC; Mutsaers HA; Dijkman HB; van den Heuvel LP; Hoenderop JG; Sweep FC; Russel FG; Masereeuw R
    Biochim Biophys Acta; 2013 Oct; 1832(10):1715-22. PubMed ID: 23665398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of human organic anion as well as cation transporters with indoxyl sulfate.
    Enomoto A; Takeda M; Taki K; Takayama F; Noshiro R; Niwa T; Endou H
    Eur J Pharmacol; 2003 Apr; 466(1-2):13-20. PubMed ID: 12679137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro evidence of enhanced breast cancer resistance protein-mediated intestinal urate secretion by uremic toxins in Caco-2 cells.
    Lu Y; Nakanishi T; Hosomi A; Komori H; Tamai I
    J Pharm Pharmacol; 2015 Feb; 67(2):170-7. PubMed ID: 25515305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions Between Meropenem and Renal Drug Transporters.
    Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
    Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
    Mutsaers HA; van den Heuvel LP; Ringens LH; Dankers AC; Russel FG; Wetzels JF; Hoenderop JG; Masereeuw R
    PLoS One; 2011 Apr; 6(4):e18438. PubMed ID: 21483698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.
    Taniguchi T; Omura K; Motoki K; Sakai M; Chikamatsu N; Ashizawa N; Takada T; Iwanaga T
    Sci Rep; 2021 Mar; 11(1):7232. PubMed ID: 33790363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
    Deguchi T; Ohtsuki S; Otagiri M; Takanaga H; Asaba H; Mori S; Terasaki T
    Kidney Int; 2002 May; 61(5):1760-8. PubMed ID: 11967025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
    Shoaf SE; Bricmont P; Repella Gordon J
    Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
    Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
    Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
    Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C
    Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants.
    Shen H; Huo R; Zhang Y; Wang L; Tong N; Chen W; Paris AJ; Mensah K; Chen M; Xue Y; Li W; Sinz M
    J Pharmacol Exp Ther; 2024 Jul; 390(2):162-173. PubMed ID: 38296646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression.
    Takada T; Yamamoto T; Matsuo H; Tan JK; Ooyama K; Sakiyama M; Miyata H; Yamanashi Y; Toyoda Y; Higashino T; Nakayama A; Nakashima A; Shinomiya N; Ichida K; Ooyama H; Fujimori S; Suzuki H
    Sci Rep; 2018 Jul; 8(1):11147. PubMed ID: 30042379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
    Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins.
    Kong F; Pang X; Zhong K; Guo Z; Li X; Zhong D; Chen X
    Drug Metab Dispos; 2017 Jun; 45(6):593-603. PubMed ID: 28314825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.